OVCAS1
MCID: OVR114
MIFTS: 51

Ovarian Cancer 1 (OVCAS1)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Cancer 1

MalaCards integrated aliases for Ovarian Cancer 1:

Name: Ovarian Cancer 1 58 30
Ovarian Carcinoma 12 15 74
Ovarian Cancer, Susceptibility to, 1 58 13
Ovarian Cancer, Susceptibility to 58
Malignant Neoplasm of Ovary 74
Epithelial Ovarian Cancer 74
Ovarian Cancer 58
Ovcas1 58

Classifications:



External Ids:

Disease Ontology 12 DOID:4001
OMIM 58 607893
MeSH 45 C538090
NCIt 51 C4908

Summaries for Ovarian Cancer 1

MalaCards based summary : Ovarian Cancer 1, also known as ovarian carcinoma, is related to ovarian cancer and hereditary breast ovarian cancer syndrome, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer 1 is OVCAS1 (Ovarian Cancer, Epithelial, Susceptibility To). The drugs Bevacizumab and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include t cells, ovary and testes.

Description from OMIM: 607893

Related Diseases for Ovarian Cancer 1

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1

Diseases related to Ovarian Cancer 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 532)
# Related Disease Score Top Affiliating Genes
1 ovarian cancer 12.9
2 hereditary breast ovarian cancer syndrome 12.6
3 breast-ovarian cancer, familial 1 12.5
4 breast-ovarian cancer, familial 2 12.5
5 breast-ovarian cancer, familial 3 12.5
6 breast-ovarian cancer, familial 4 12.5
7 childhood ovarian cancer 12.4
8 brca2 hereditary breast and ovarian cancer syndrome 12.3
9 hereditary site-specific ovarian cancer syndrome 12.0
10 familiar ovarian carcinoma 12.0
11 ovarian epithelial cancer 11.9
12 ovarian clear cell carcinoma 11.5
13 pancreatic cancer 11.5
14 paraneoplastic cerebellar degeneration 11.5
15 breast cancer 11.5
16 lynch syndrome 11.4
17 malignant ovarian cyst 11.3
18 brca1 hereditary breast and ovarian cancer syndrome 11.2
19 ovarian germ cell cancer 11.1
20 ovarian small cell carcinoma 11.1
21 ovarian large-cell neuroendocrine carcinoma 11.1
22 ovarian squamous cell carcinoma 11.1
23 ovary papillary carcinoma 11.1
24 ovarian seromucinous carcinoma 11.1
25 ovarian melanoma 11.0
26 ovarian disease 11.0
27 ovarian malignant mesothelioma 11.0
28 ovary sarcoma 11.0
29 ovarian lymphoma 11.0
30 ovary epithelial cancer 11.0
31 ovary neuroendocrine neoplasm 11.0
32 ovarian clear cell malignant adenofibroma 11.0
33 granulosa cell tumor of the ovary 11.0
34 gynandroblastoma 11.0
35 endometriosis 10.6
36 hypoxia 10.5
37 horns in sheep 10.3
38 adenocarcinoma 10.3
39 ovarian cyst 10.3
40 thrombocytosis 10.3
41 retinoblastoma 10.3
42 colorectal cancer 10.3
43 dermatomyositis 10.3
44 intestinal obstruction 10.3
45 insulin-like growth factor i 10.2
46 endometrial cancer 10.2
47 body mass index quantitative trait locus 1 10.2
48 sclerosing cholangitis, neonatal 10.2
49 pelvic inflammatory disease 10.2
50 fallopian tube carcinoma 10.2

Graphical network of the top 20 diseases related to Ovarian Cancer 1:



Diseases related to Ovarian Cancer 1

Symptoms & Phenotypes for Ovarian Cancer 1

Clinical features from OMIM:

607893

UMLS symptoms related to Ovarian Cancer 1:


pelvic pain

Drugs & Therapeutics for Ovarian Cancer 1

Drugs for Ovarian Cancer 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 723)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
2
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
4
Peppermint Approved Phase 4
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1177-87-3
7
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
8
Ferrous fumarate Approved Phase 4,Early Phase 1,Not Applicable 141-01-5
9
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
10
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 114977-28-5 148124
11
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 763113-22-0 23725625
12
Tranexamic Acid Approved Phase 4 1197-18-8 5526
13
Niraparib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1038915-60-4 24958200
14
Aprepitant Approved, Investigational Phase 4,Phase 2,Not Applicable 170729-80-3 6918365 151165
15
Fosaprepitant Approved Phase 4,Phase 2,Not Applicable 172673-20-0 219090
16
Iron Approved, Experimental Phase 4,Phase 1,Phase 2,Not Applicable 7439-89-6, 15438-31-0 27284 23925
17
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 68-26-8, 22737-96-8, 11103-57-4 9904001 445354
18
Vitamin C Approved, Nutraceutical Phase 4,Phase 1,Phase 2 50-81-7 54670067 5785
19
Tyrosine Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 60-18-4 6057
20
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 31703
21 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Coagulants Phase 4,Phase 2,Phase 1,Not Applicable
29 Hemostatics Phase 4,Phase 2,Phase 1,Not Applicable
30 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
33 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
35 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 BB 1101 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
38 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
40
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 taxane Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Nutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2590)
# Name Status NCT ID Phase Drugs
1 Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab Unknown status NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
2 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
3 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
4 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Active, not recruiting NCT02476968 Phase 4 Olaparib
5 Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
6 Diaphragmatic Resection And Gynecological Ovarian Neoplasm Recruiting NCT03543462 Phase 4
7 Tranexamic Acid in Surgery of Advanced Ovarian Cancer Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
8 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
9 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
10 NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. Not yet recruiting NCT03752216 Phase 4 Niraparib
11 Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer Not yet recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
12 Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer Recruiting NCT03858166 Phase 4 PEG-rhG-CSF
13 Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations Recruiting NCT03475589 Phase 4 apatinib
14 PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
15 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
16 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
17 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
18 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
19 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Recruiting NCT03349463 Phase 4 Fluciclovine F18
20 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
21 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
22 Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
23 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
24 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
25 Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
26 Hydralazine Valproate for Ovarian Cancer Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
27 Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study Unknown status NCT00715286 Phase 3
28 Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
29 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
30 Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
31 Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer Unknown status NCT01802749 Phase 3 Bevacizumab;Paclitaxel;Carboplatin;pegylated liposomal doxorubicin;Gemcitabine
32 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
33 Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer Unknown status NCT01628380 Phase 3
34 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
35 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
36 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
37 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
38 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
39 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
40 Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy Unknown status NCT02097446 Phase 3
41 Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas Unknown status NCT00689715 Phase 2, Phase 3
42 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
43 Violence Against Women and Consequences During Climacteric´s Phase Completed NCT01028118 Phase 3
44 Pelvic and Aortic-cava Lymphadenectomy Randomized for Ovarian Cancer Suspended NCT01218490 Phase 3
45 Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm Active, not recruiting NCT01461850 Phase 3 Neoadjuvant chemotherapy + Interval Debulking Surgery
46 A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy Terminated NCT01840943 Phase 3 CAELYX;Topotecan HCl
47 CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy Terminated NCT00653952 Phase 3 CAELYX;Paclitaxel HCl
48 Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer Not yet recruiting NCT03949283 Phase 3 Standard Chemotherapy
49 A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients Not yet recruiting NCT03863860 Phase 3 Fluzoparib capsules;Placebo capsules
50 Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer Recruiting NCT02681432 Phase 3 HIPEC

Search NIH Clinical Center for Ovarian Cancer 1

Genetic Tests for Ovarian Cancer 1

Genetic tests related to Ovarian Cancer 1:

# Genetic test Affiliating Genes
1 Ovarian Cancer 1 30

Anatomical Context for Ovarian Cancer 1

MalaCards organs/tissues related to Ovarian Cancer 1:

42
T Cells, Ovary, Testes, Bone, Prostate, Lymph Node, Breast

Publications for Ovarian Cancer 1

Articles related to Ovarian Cancer 1:

(show top 50) (show all 3681)
# Title Authors Year
1
Effect of Chemotherapeutics and Tocopherols on MCF-7 Breast Adenocarcinoma and KGN Ovarian Carcinoma Cell Lines In Vitro. ( 30766885 )
2019
2
Transformation of follicular lymphoma to double-hit lymphoma during adjuvant chemotherapy for concurrent ovarian carcinoma. ( 31104212 )
2019
3
LINK-A Long Non-Coding RNA (lncRNA) Participates in Metastasis of Ovarian Carcinoma and Upregulates Hypoxia-Inducible Factor 1 (HIF1α). ( 30912527 )
2019
4
RGS5 decreases the proliferation of human ovarian carcinoma‑derived primary endothelial cells through the MAPK/ERK signaling pathway in hypoxia. ( 30365142 )
2019
5
Hydropic leiomyoma presenting as a rare condition of pseudo-Meigs syndrome: literature review and a case of a pseudo-Meigs syndrome mimicking ovarian carcinoma with elevated CA125. ( 30635302 )
2019
6
A rare case of linitis plastica of the colon from ovarian carcinoma. ( 30949339 )
2019
7
Association between p53 protein phosphorylated at serine 20 expression and ovarian carcinoma stem cells phenotype: correlation with clinicopathological parameters of ovarian cancer. ( 31088101 )
2019
8
Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network. ( 30428389 )
2019
9
First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma. ( 31058421 )
2019
10
Effects of human umbilical cord mesenchymal stem cells on co-cultured ovarian carcinoma cells. ( 30790367 )
2019
11
Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma. ( 30734108 )
2019
12
The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients. ( 30737418 )
2019
13
Theaflavin-3,3'-Digallate Suppresses Human Ovarian Carcinoma OVCAR-3 Cells by Regulating the Checkpoint Kinase 2 and p27 kip1 Pathways. ( 30769778 )
2019
14
Mortalin is a distinct bio-marker and prognostic factor in serous ovarian carcinoma. ( 30776464 )
2019
15
PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma. ( 30778048 )
2019
16
Novel triazole analogs of apigenin-7-methyl ether exhibit potent antitumor activity against ovarian carcinoma cells via the induction of mitochondrial-mediated apoptosis. ( 30783435 )
2019
17
Prognostic Factors of Early Stage Epithelial Ovarian Carcinoma. ( 30795566 )
2019
18
Astaxanthin Combine With Human Serum Albumin To Abrogate Cell Proliferation, Migration, And Drug-Resistant In Human Ovarian Carcinoma SKOV3 Cells. ( 30799797 )
2019
19
Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. ( 30803719 )
2019
20
Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma. ( 30833444 )
2019
21
Novel Bi-Functional 14-mer Peptides with Both Ovarian Carcinoma Cells Targeting and Magnetic Fe₃O₄Nanoparticles Affinity. ( 30841597 )
2019
22
The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1). ( 30853361 )
2019
23
Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium. ( 30862952 )
2019
24
HULC functions as an oncogene in ovarian carcinoma cells by negatively modulating miR-125a-3p. ( 30863948 )
2019
25
Honokiol induces apoptosis and suppresses migration and invasion of ovarian carcinoma cells via AMPK/mTOR signaling pathway. ( 30864681 )
2019
26
Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma. ( 30883751 )
2019
27
Dynamic analysis of proteomic alterations in response to N-linked glycosylation inhibition in a drug-resistant ovarian carcinoma cell line. ( 30884134 )
2019
28
Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma. ( 30887755 )
2019
29
Removal of the entire internal iliac vessel system is a feasible surgical procedure for locally advanced ovarian carcinoma adhered firmly to the pelvic sidewall. ( 30891652 )
2019
30
Enhanced anti-proliferative and pro-apoptotic effects of metformin encapsulated PLGA-PEG nanoparticles on SKOV3 human ovarian carcinoma cells. ( 30892093 )
2019
31
LncRNA AWPPH promotes the proliferation, migration and invasion of ovarian carcinoma cells via activation of the Wnt/β‑catenin signaling pathway. ( 30896797 )
2019
32
Combination of shikonin with paclitaxel overcomes multidrug resistance in human ovarian carcinoma cells in a P-gp-independent manner through enhanced ROS generation. ( 30911326 )
2019
33
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma: Correction. ( 30913186 )
2019
34
lncRNA mortal obligate RNA transcript was downregulated in ovarian carcinoma and inhibits cancer cell proliferation by downregulating miRNA-21. ( 30916806 )
2019
35
Mucinous Ovarian Carcinoma. ( 30917260 )
2019
36
Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition. ( 30929564 )
2019
37
Comparison of long-term oncologic outcomes between metastatic ovarian carcinoma originating from gastrointestinal organs and advanced mucinous ovarian carcinoma. ( 30941534 )
2019
38
Gentiopicroside exerts convincing antitumor effects in human ovarian carcinoma cells (SKOV3) by inducing cell cycle arrest, mitochondrial mediated apoptosis and inhibition of cell migration. ( 30941981 )
2019
39
Expression of miR-26b in ovarian carcinoma tissues and its correlation with clinicopathology. ( 30944634 )
2019
40
Proteomics derived biomarker panel improves diagnostic precision to classify endometrioid and high-grade serous ovarian carcinoma. ( 30979743 )
2019
41
Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma. ( 31002564 )
2019
42
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. ( 31002578 )
2019
43
Expanding the Chemical Space of Withaferin A by Incorporating Silicon to Improve its Clinical Potential on Human Ovarian Carcinoma Cells. ( 31008605 )
2019
44
Efficacy of a Selective Binder of αVβ3 Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models. ( 31013908 )
2019
45
Overexpression of thymic stromal lymphopoietin is correlated with poor prognosis in epithelial ovarian carcinoma. ( 31023965 )
2019
46
Inhibition of RNA-Binding Protein Musashi-1 Suppresses Malignant Properties and Reverses Paclitaxel Resistance in Ovarian Carcinoma. ( 31031868 )
2019
47
Aberrant Expression of Folate Metabolism Enzymes and Its Diagnosis and Survival Prediction in Ovarian Carcinoma. ( 31049278 )
2019
48
Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse. ( 31055034 )
2019
49
Onset of Telomere Dysfunction and Fusions in Human Ovarian Carcinoma. ( 31060240 )
2019
50
Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma. ( 31069161 )
2019

Variations for Ovarian Cancer 1

Expression for Ovarian Cancer 1

Search GEO for disease gene expression data for Ovarian Cancer 1.

Pathways for Ovarian Cancer 1

GO Terms for Ovarian Cancer 1

Sources for Ovarian Cancer 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....